PE20000010A1 - DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3 - Google Patents

DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3

Info

Publication number
PE20000010A1
PE20000010A1 PE1998001244A PE00124498A PE20000010A1 PE 20000010 A1 PE20000010 A1 PE 20000010A1 PE 1998001244 A PE1998001244 A PE 1998001244A PE 00124498 A PE00124498 A PE 00124498A PE 20000010 A1 PE20000010 A1 PE 20000010A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
oxo
compound
integrin receptor
Prior art date
Application number
PE1998001244A
Other languages
English (en)
Inventor
John H Hutchinson
Michael A Patane
Mark E Duggan
Robert S Meissner
Wasyl Halczenko
James J Perkins
Ben C Askew
Paul J Coleman
Jiabing Wang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810182.7A external-priority patent/GB9810182D0/en
Priority claimed from GBGB9810882.2A external-priority patent/GB9810882D0/en
Priority claimed from GBGB9810892.1A external-priority patent/GB9810892D0/en
Priority claimed from GBGB9811283.2A external-priority patent/GB9811283D0/en
Priority claimed from GBGB9812686.5A external-priority patent/GB9812686D0/en
Priority claimed from GBGB9822331.6A external-priority patent/GB9822331D0/en
Priority claimed from GBGB9822701.0A external-priority patent/GB9822701D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20000010A1 publication Critical patent/PE20000010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

SE REFIERE A UN COMPUESTO I, LOS ATOMOS DEL DOBLE ENLACE SE SUSTITUYEN CON R11 Y R12; "X" ES -C(=NR1)-NR1R2, -NR1-C(=NR2)-NR1R2, ANILLO AROMATICO DE 5 o 6 MIEMBROS CON 0-4 N, O, S; ANILLO POLICICLICO DE 9-14 MIEMBROS CON 0-4 N, O, S; "Y" ES -(CH2)m-, -(CH2)m-O-(CH2)n-, -(CH2)mNR4-(CH2)n-, ENTRE OTROS; "Z" ES ANILLO MONO O POLICICLICO CON 0-4 N, O, S; CUALQUIER METILENO EN "Y" QUE NO TENGA R4 SE PUEDE SUSTITUIR CON 1-2 R3; R1 Y R2 SON H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; R3 ES H, ARILO, ALQUILO C1-C10, ENTRE OTROS, R4 ES H, ARILO, AMINOCARBONILO, ENTRE OTROS; R5 Y R6 SON H, ALQUILO C1-C6, ARILO, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C6, ARILO, ENTRE OTROS; R9 ES H, ALQUILO C1-C8; R10, R11, R12 Y R13 SON H, ALQUILO C1-C8, ARILO, ENTRE OTROS; m Y n SON 0-6; v ES 0-2. UN COMPUESTO PREFERIDO ES ACIDO 3(S)-(2,3-DIHIDRO-BENZOFURAN-6-ILO)-3-{2-OXO-3-[3-(5,6,7,8-TETRAHIDRO-[1,8]NAFTIRIDIN-2-ILO}-PROPIONICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES ANTAGONISTA DEL RECEPTOR INTEGRINA Ovß3, Ovß5, Ovß6 Y ES UTIL PARA INHIBIR LA RESORCION DEL HUESO, TRATAMIENTO Y PREVENCION DE OSTEOPOROSIS, INHIBICION DE RESTENOSIS VASCULAR, RETINOPATIA DIABETICA, DEGENERACION MACULAR, ANGIOGENESIS, ATEROSCLEROSIS, INFLAMACION, CURAR HERIDAS, ENFERMEDADES VIRALES, CRECIMIENTO DE TUMORES, METASTASIS
PE1998001244A 1997-12-17 1998-12-17 DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3 PE20000010A1 (es)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US6991097P 1997-12-17 1997-12-17
US7919798P 1998-03-24 1998-03-24
US7994498P 1998-03-30 1998-03-30
US8039798P 1998-04-02 1998-04-02
US8325198P 1998-04-27 1998-04-27
GBGB9810182.7A GB9810182D0 (en) 1998-05-13 1998-05-13 Vitronectin receptor antagonists
GBGB9810882.2A GB9810882D0 (en) 1998-05-20 1998-05-20 Vitronectin receptor antagonists
GBGB9810892.1A GB9810892D0 (en) 1998-05-20 1998-05-20 Vitronectin receptor antagonists
GBGB9811283.2A GB9811283D0 (en) 1998-05-26 1998-05-26 Vironectin receptor antagonists
GBGB9812686.5A GB9812686D0 (en) 1998-06-12 1998-06-12 Vitronectin receptor antagonists
US9258898P 1998-07-13 1998-07-13
US9262498P 1998-07-13 1998-07-13
US9994898P 1998-09-11 1998-09-11
GBGB9822331.6A GB9822331D0 (en) 1998-10-13 1998-10-13 Vitronectin receptor antagonists
GBGB9822701.0A GB9822701D0 (en) 1998-10-16 1998-10-16 Intergrin receptor antagonists

Publications (1)

Publication Number Publication Date
PE20000010A1 true PE20000010A1 (es) 2000-01-29

Family

ID=27585232

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001244A PE20000010A1 (es) 1997-12-17 1998-12-17 DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3

Country Status (23)

Country Link
EP (1) EP1040111B1 (es)
JP (2) JP3589633B2 (es)
KR (2) KR20010024748A (es)
AT (1) ATE298338T1 (es)
AU (1) AU741769B2 (es)
BG (1) BG104601A (es)
CA (1) CA2315189C (es)
DK (1) DK1040111T3 (es)
EA (1) EA003095B1 (es)
EE (1) EE200000360A (es)
ES (1) ES2243016T3 (es)
HU (1) HUP0100178A3 (es)
IL (1) IL136314A0 (es)
IS (1) IS5513A (es)
NO (1) NO317975B1 (es)
NZ (1) NZ504896A (es)
PE (1) PE20000010A1 (es)
PL (1) PL341095A1 (es)
PT (1) PT1040111E (es)
SI (1) SI1040111T1 (es)
SK (1) SK9162000A3 (es)
TR (1) TR200001752T2 (es)
WO (1) WO1999031099A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030709A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
JP2002522540A (ja) * 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CN1398189A (zh) * 1998-12-23 2003-02-19 G.D.西尔公司 用于***形成的放疗与cox－2抑制剂的联合治疗
KR20010108499A (ko) 1999-04-13 2001-12-07 스타르크, 카르크 인테그린 수용체 리간드
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
BR0011108A (pt) 1999-06-02 2002-03-19 Merck & Co Inc Composto, composição farmacêutica, e, processos de eliciar um efeito antagonizante do receptor da integrina, de tratamento ou prevenção da osteoporose, de tratamento ou prevenção de uma condição mediada por antagonismo de um receptor de integrina, de inibição da reabsorção óssea em um mamìfero em necessidade do mesmo, e de tratamento do desenvolvimento tumoral
DE19936780A1 (de) * 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
JP2003510360A (ja) * 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
WO2001034602A2 (en) * 1999-11-08 2001-05-17 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
GB2356630A (en) 1999-11-10 2001-05-30 Merck & Co Inc Intermediates used in the preparation of tetrahydronaphthyridine
AU768875B2 (en) 1999-11-23 2004-01-08 Merck Sharp & Dohme Corp. Process and intermediates to a tetrahydro-(1,8)-naphthyridine
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
CA2397194C (en) * 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
ATE375330T1 (de) 2000-04-17 2007-10-15 Ucb Pharma Sa Enamin-derivate als zell-adhäsionsmoleküle
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
EP1301488A1 (en) 2000-07-07 2003-04-16 Celltech R&D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
AU9088401A (en) * 2000-09-13 2002-03-26 Merck & Co Inc Alpha v integrin receptor antagonists
CA2421652A1 (en) 2000-09-14 2002-03-21 Merck And Co., Inc. Alpha v integrin receptor antagonists
JP2004517853A (ja) * 2001-01-03 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド 歯周病の治療方法及び治療用組成物
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
ATE510557T1 (de) 2001-04-24 2011-06-15 Merck Patent Gmbh Kombinationstherapie mit antiangiogenen mitteln und tnfalpha
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20070299114A1 (en) * 2004-10-05 2007-12-27 Shionogi & Co., Ltd. Biaryl Derivatives
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
ES2399159T3 (es) 2007-01-18 2013-03-26 Merck Patent Gmbh Terapia y medicamento específicos usando ligandos de integrinas para el tratamiento del cáncer
CN104225613A (zh) 2008-03-14 2014-12-24 Visen医药公司 整联蛋白靶向试剂及使用其的体内和体外成像方法
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
CA2763275A1 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
BR112012021498B8 (pt) 2010-02-27 2020-04-14 Bayer Ip Gmbh ariltriazolonas ligadas a bisaril e seu uso
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
US9518053B2 (en) 2013-02-07 2016-12-13 Scifluor Life Sciences, Inc. Fluorinated integrin antagonists
PL3050878T3 (pl) 2013-09-24 2022-01-24 Fujifilm Corporation Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem
MX2016015467A (es) 2014-05-30 2017-03-23 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
CU24462B1 (es) 2014-11-03 2020-01-03 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo
KR102647026B1 (ko) * 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
EP3589627A4 (en) 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN
UY38353A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibición de integrina alfavbeta6
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598073A (en) * 1976-12-18 1981-09-16 Beecham Group Ltd 8,10,12-triazaprostaglandins
DE2965098D1 (en) * 1978-06-15 1983-05-05 Beecham Group Plc 1.2.4-triazolidine-3.5-dione derivatives, process for their preparation and pharmaceutical compositions containing them
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
WO1991018888A1 (en) * 1990-05-25 1991-12-12 G.D. Searle & Co. N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2129897C (en) * 1992-02-11 2006-01-10 James David Winkler Coa-it and paf inhibitors
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物

Also Published As

Publication number Publication date
EA003095B1 (ru) 2002-12-26
AU741769B2 (en) 2001-12-06
CA2315189A1 (en) 1999-06-24
JP2002508374A (ja) 2002-03-19
DK1040111T3 (da) 2005-10-10
PL341095A1 (en) 2001-03-26
SI1040111T1 (en) 2005-10-31
ES2243016T3 (es) 2005-11-16
BG104601A (bg) 2001-01-31
AU1914499A (en) 1999-07-05
NO20003113D0 (no) 2000-06-16
ATE298338T1 (de) 2005-07-15
WO1999031099A1 (en) 1999-06-24
JP3589633B2 (ja) 2004-11-17
NO20003113L (no) 2000-08-16
KR20010024748A (ko) 2001-03-26
PT1040111E (pt) 2005-10-31
NZ504896A (en) 2002-10-25
EP1040111B1 (en) 2005-06-22
IL136314A0 (en) 2001-05-20
TR200001752T2 (tr) 2000-12-21
KR20030048081A (ko) 2003-06-18
EP1040111A1 (en) 2000-10-04
EE200000360A (et) 2001-12-17
SK9162000A3 (en) 2001-03-12
HUP0100178A3 (en) 2002-12-28
CA2315189C (en) 2005-04-19
JP2004300158A (ja) 2004-10-28
HUP0100178A2 (hu) 2001-11-28
EA200000653A1 (ru) 2000-12-25
IS5513A (is) 2000-05-26
NO317975B1 (no) 2005-01-17

Similar Documents

Publication Publication Date Title
PE20000010A1 (es) DERIVADOS DE 2-OXO-IMIDAZOLIDINA, COMO ANTAGONISTAS DEL RECEPTOR DE INTEGRINA avß3
TWI265931B (en) Composition and method for inhibiting platelet aggregation
PT1074542E (pt) Compostos de indole contendo sulfonamida
NZ504893A (en) 5, 6, 7, 8-Tetrahydro-[1,8]-naphthyridin-2-yl derivatives useful as integrin receptor antagonists
BR0112475A (pt) N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina
DE60035496D1 (de) Indolinderivate als progesteron antagonisten
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
EA200401056A1 (ru) Комбинация, содержащая производные тропана, полезные в терапии
BRPI0412314A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
ES2164939T3 (es) Derivados de 1-(1,2-piperidinil disustituido)-4-piperidina sustituida como antagonistas de receptores de taquicinina.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
HUP0001162A2 (hu) Pirrolo-benzodiazepin-, -kinoxalin-, -pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
AR034270A1 (es) 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
ECSP034796A (es) DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
ME00149B (me) Postupci i farmaceutski sastavi za pouzdano postizanje prihvatljivih nivoa seruma testosterona
IL104090A (en) Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing these compounds
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
AR015222A1 (es) Benzotiadiazoles, proceso para su preparacion, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
MX9806171A (es) Derivados 2,3-benzodiazepina y sus usos como inhibidores del receptor-ampa.
MY129176A (en) Tetrahydro gamma-carbolines
BR9806263A (pt) Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed